Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPSODY: two interferon alfa schedules combined with sorafenib in metastatic clear cell renal cell carcinoma
2005-005770-72Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Feb 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib and interferon alfa in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Progression-free survival rate. Started Feb 2006; status: active.
02
Drugs
sorafenibinterferon alfa
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2005-005770-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005770-72.